Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.61 |
| ▸ | CA1 | P00915 | 15/20 | 0.61 |
| ▸ | CA2 | P00918 | 15/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 6/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15150500 | 0.91 | CA9 (0.59) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL15145504 | 0.91 | CA9 (0.63) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL18595016 | 0.91 | CA9 (0.59) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14527509 | 0.88 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL17067944 | 0.88 | CA9 (0.61) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14426895 | 0.86 | USP2 (0.68) | CA9CA1CA2USP2L3MBTL1 | |
| 5-Iodoacetamidofluorescein SCHEMBL10146553 | 0.86 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL12793932 | 0.86 | CA9 (0.66) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL15372440 | 0.86 | CA9 (0.59) | CA9CA1CA2USP2L3MBTL1 | |
| SCHEMBL14401673 | 0.86 | CA9 (0.61) | CA9CA1CA2USP2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | HOFFMANN-LA ROCHE INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | ITGAV, ITGA1, ITGA4 | CA9 2803/4885CA1 3280/4885CA2 3419/4885 |
| US-20150038523-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | CA9 2276/4885CA1 2230/4885CA2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.